Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology and Hepatology
Volume 2017, Article ID 9365657, 8 pages
https://doi.org/10.1155/2017/9365657
Research Article

The Geography of Primary Hepatic Neoplasms Treatments in Canada: Changes in Latitudes and Changes in Attitudes

1Department of Surgery, Dalhousie University, Halifax, NS, Canada
2Surveillance and Epidemiology Unit, Cancer Care Nova Scotia, Halifax, NS, Canada
3Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA

Correspondence should be addressed to Michele Molinari; ude.cmpu@miranilom

Received 24 April 2017; Revised 23 June 2017; Accepted 27 June 2017; Published 26 July 2017

Academic Editor: Tatsuo Kanda

Copyright © 2017 Matthew Cwinn et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Ananthakrishnan, V. Gogineni, and K. Saeian, “Epidemiology of primary and secondary liver cancers,” Seminars in Interventional Radiology, vol. 23, no. 1, pp. 47–63, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Aljiffry, M. J. Walsh, and M. Molinari, “Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990–2009,” World Journal of Gastroenterology, vol. 15, no. 34, pp. 4240–4262, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. H. B. El-Serag, “Hepatocellular carcinoma,” The New England Journal of Medicine, vol. 365, no. 12, pp. 1118–1127, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. “World Health Statistics 2014,” 2014, http://www.who.int/gho/publications/world_health_statistics/2014/en/.
  5. K. Khalili, R. Menezes, L. K. Yazdi et al., “Hepatocellular carcinoma in a large Canadian urban centre: Stage at treatment and its potential determinants,” Canadian Journal of Gastroenterology and Hepatology, vol. 28, no. 3, pp. 150–154, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. Statistics CCSsACoC, Canadian Cancer Statistics, Canadian Cancer Society, Ontario, Canada, 2015.
  7. “Liver Cancer - Canadian Statistics for 2015,” 2015, http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/indi02a-eng.htm.
  8. R. T.-P. Poon, T. F. Sheung, M. L. Chung, L. L. Chi, and J. Wong, “Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation,” Annals of Surgery, vol. 235, no. 3, pp. 373–382, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Osaki and H. Nishikawa, “Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review,” Hepatology Research, vol. 45, no. 1, pp. 59–74, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. E. A. Akriviadis, J. M. Llovet, S. C. Efremidis et al., “Hepatocellular carcinoma,” British Journal of Surgery, vol. 85, no. 10, pp. 1319–1331, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. F. F. Amersi, A. McElrath-Garza, A. Ahmad et al., “Long-term survival after radiofrequency ablation of complex unresectable liver tumors,” Archives of Surgery, vol. 141, no. 6, pp. 581–587, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Bismuth, P. E. Majno, and R. Adam, “Liver transplantation for hepatocellular carcinoma,” Seminars in Liver Disease, vol. 19, no. 3, pp. 311–321, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Bruix and M. Sherman, “Management of hepatocellular carcinoma: an update,” Hepatology, vol. 53, no. 3, pp. 1020–1022, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Huang, L. Yan, Z. Cheng et al., “A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria,” Annals of Surgery, vol. 252, no. 6, pp. 903–912, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Bruix and M. Sherman, “Management of Hepatocellular carcinoma,” Hepatology, vol. 42, no. 5, pp. 1208–1236, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. R. T.-P. Poon, H. Ngan, C.-M. Lo, C.-L. Liu, S.-T. Fan, and J. Wong, “Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence,” Journal of Surgical Oncology, vol. 73, no. 2, pp. 109–114, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. A. S. Kennedy and R. Salem, “Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies,” Cancer Journal, vol. 16, no. 2, pp. 163–175, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Salem, R. J. Lewandowski, M. F. Mulcahy et al., “Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes,” Gastroenterology, vol. 138, no. 1, pp. 52–64, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. D. L. Andolino, C. S. Johnson, M. Maluccio et al., “Stereotactic body radiotherapy for primary hepatocellular carcinoma,” International Journal of Radiation Oncology Biology Physics, vol. 81, no. 4, pp. e447–e453, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Molinari and S. Helton, “Hepatic resection versus radiofrequency ablation for hepatocellular carcinoma in cirrhotic individuals not candidates for liver transplantation: A Markov model decision analysis,” American Journal of Surgery, vol. 198, no. 3, pp. 396–406, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Brunello, A. Veltri, P. Carucci et al., “Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial,” Scandinavian Journal of Gastroenterology, vol. 43, no. 6, pp. 727–735, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. M.-S. Chen, J.-Q. Li, Y. Zheng et al., “A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma,” Annals of Surgery, vol. 243, no. 3, pp. 321–328, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. S. D. Ryder and British Society of G, “Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults,” Gut, vol. 52, Supplement 3, pp. iii1–iii8, 2003. View at Publisher · View at Google Scholar
  24. J. M. Llovet, S. Ricci, V. Mazzaferro et al., “Sorafenib in advanced hepatocellular carcinoma,” The New England Journal of Medicine, vol. 359, no. 4, pp. 378–390, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Farinati, N. De Maria, C. Marafin et al., “Unresectable Hepatocellular Carcinoma in Cirrhosis: Survival, Prognostic Factors, and Unexpected Side Effects after Transcatheter Arterial Chemoembolization,” Digestive Diseases and Sciences, vol. 41, no. 12, pp. 2332–2339, 1996. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Yamasaki, N. Umeno, S. Harada, K. Tanaka, M. Kato, and K. Kotoh, “Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib,” Journal of Gastrointestinal Oncology, vol. 7, no. 3, pp. E36–E40, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. H.-H. Thein, W. Isaranuwatchai, M. A. Campitelli et al., “Health care costs associated with hepatocellular carcinoma: A population-based study,” Hepatology, vol. 58, no. 4, pp. 1375–1384, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. O. Hyder, R. M. Dodson, H. Nathan et al., “Referral patterns and treatment choices for patients with hepatocellular carcinoma: A United States population-based study,” Journal of the American College of Surgeons, vol. 217, no. 5, pp. 896–906, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Zhang, M. N. Mavros, D. Cosgrove et al., “Impact of a single-day multidisciplinary clinic on the management of patients with liver tumours,” Current Oncology, vol. 20, no. 2, pp. e123–e131, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Chamberlain, D. Sarfati, R. Cunningham, J. Koea, J. Gurney, and T. Blakely, “Incidence and management of hepatocellular carcinoma among Māori and non-Māori New Zealanders,” Australian and New Zealand Journal of Public Health, vol. 37, no. 6, pp. 520–526, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. R. S. Hoehn, D. J. Hanseman, K. Wima et al., “Does race affect management and survival in hepatocellular carcinoma in the United States?” Surgery (United States), vol. 158, no. 5, article no. 4115, pp. 1244–1251, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Tan, A. Yopp, M. S. Beg, P. Gopal, and A. G. Singal, “Meta-analysis: Underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States,” Alimentary Pharmacology and Therapeutics, vol. 38, no. 7, pp. 703–712, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Pocobelli, L. S. Cook, R. Brant, and S. S. Lee, “Hepatocellular carcinoma incidence trends in Canada: Analysis by birth cohort and period of diagnosis,” Liver International, vol. 28, no. 9, pp. 1272–1279, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Sherman, K. Burak, J. Maroun et al., “Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma,” Current Oncology, vol. 18, no. 5, pp. 228–240, 2011. View at Publisher · View at Google Scholar
  35. “Canadian Health Care,” In, http://www.canadian-healthcare.org/.
  36. “Provincial and Territorial Ranking,” 2014, http://www.conferenceboard.ca/hcp/provincial/economy.aspx.
  37. S. Hurton, F. MacDonald, G. Porter, M. Walsh, and M. Molinari, “The current state of pancreatic cancer in Canada: Incidence, mortality, and surgical therapy,” Pancreas, vol. 43, no. 6, pp. 879–885, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. Information CIfH, “Canadian Classification of Health Interventions,” 2015, pp. 440.
  39. N. E. Breslow, Statistical Methods in Cancer Research, vol. 2, IARC Scientific Publication, Lyon, France, 1987.
  40. E. B. Wilson and M. M. Hilferty, “The Distribution of Chi-Square,” Proceedings of the National Academy of Sciences, vol. 17, no. 12, pp. 684–688, 1931. View at Publisher · View at Google Scholar
  41. “Standardized Incidence Ratios,” Edited by University B, http://sphweb.bumc.bu.edu/otlt/MPH-Modules/EP/EP713_StandardizedRates/EP713_StandardizedRates6.html.
  42. J.-N. Vauthey, E. Dixon, E. K. Abdalla et al., “Pretreatment assessment of hepatocellular carcinoma: Expert consensus statement,” HPB, vol. 12, no. 5, pp. 289–299, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Molinari, P. D. Renfrew, N. M. Petrie, S. De Coutere, and M. Abdolell, “Clinical epidemiological analysis of the mortality rate of liver transplant candidates living in rural areas,” Transplant International, vol. 24, no. 3, pp. 292–299, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. K. S. Palmer, D. Martin, and G. Guyatt, “Prelude to a systematic review of activity-based funding of hospitals: potential effects on cost, quality, access, efficiency, and equity,” Open Medicine, vol. 7, no. 4, pp. 94–97, 2013. View at Google Scholar · View at Scopus
  45. Information CIfH, “A Primer Activity-Based Funding—Discussion Paper,” 2010.
  46. S. M. G. Milcic and S. Petersen, “Accelerating Healthcare Improvement in Canada: A Review of Policy Options to Sustain, Improve and Transform Healthcare,” Ottawa, 2013.
  47. Statistics Canada, “Financial Performance,” 2015, Economy Leading Indicators.
  48. P. J. Thuluvath, A. Maheshwari, N. P. Thuluvath, G. C. Nguyen, and D. L. Segev, “Survival after liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease and pre-model for end-stage liver disease eras and the independent impact of hepatitis C virus,” Liver Transplantation, vol. 15, no. 7, pp. 754–762, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Norris, Organ Donation and Transplantation in Canada, Library of Parliament, Ottawa, Canada, 2014.
  50. J. N. Izquierdo and V. J. Schoenbach, “The potential and limitations of data from population-based state cancer registries,” American Journal of Public Health, vol. 90, no. 5, pp. 695–698, 2000. View at Publisher · View at Google Scholar · View at Scopus
  51. X.-D. Zhou, Z.-Y. Tang, B.-H. Yang et al., “Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma,” Cancer, vol. 91, no. 8, pp. 1479–1486, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. M. C. Weinstein, Clinical Decision Analysis, WB Saunders, Pennsylvania, Pa, USA, 1980.